Literature DB >> 3963564

Cardiopulmonary effects of acepromazine and of the subsequent administration of ketamine in the dog.

T B Farver, S C Haskins, J D Patz.   

Abstract

Cardiopulmonary consequences of acepromazine (0.2 mg/kg of body weight, IV) followed by IV administration of ketamine (10 mg/kg) were evaluated in 13 dogs. Acepromazine caused significant decreases in arterial blood pressure, stroke volume, left ventricular work, left ventricular stroke work, breathing rate, minute ventilation, and oxygen consumption. Subsequent administration of ketamine caused significant increases in heart rate, effective alveolar volume, alveolar-arterial Po2 gradient (transient increase), venous admixture (transient increase), and PaCO2 and PVCO2 (transient increases), and caused significant decreases in stroke volume, minute ventilation, physiologic dead space, and arterial and venous PO2 (transient decreases).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3963564

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

1.  Comparison of neurologic responses to the use of medetomidine as a sole agent or preanesthetic in laboratory beagles.

Authors:  C E Short; J E Räihä; M P Räihä; K Otto
Journal:  Acta Vet Scand       Date:  1992       Impact factor: 1.695

2.  Cardiorespiratory effects of a 5HT2 antagonist (R51703) in awake and anesthetized dogs.

Authors:  T J Doherty; W N McDonell; D H Dyson; W D Black
Journal:  Can J Vet Res       Date:  1996-07       Impact factor: 1.310

3.  Cardiopulmonary effects of a ketamine/acepromazine combination in hypovolemic cats.

Authors:  W Ingwersen; D G Allen; D H Dyson; W D Black; M T Goldberg; A E Valliant
Journal:  Can J Vet Res       Date:  1988-10       Impact factor: 1.310

4.  Comparative hemodynamic effects of halothane and halothane-acepromazine at equipotent doses in dogs.

Authors:  C J Boyd; W N McDonell; A Valliant
Journal:  Can J Vet Res       Date:  1991-04       Impact factor: 1.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.